Additional Coverage:
### Published: Saturday, September 14, 2024, 8:45 AM EDT
Pfizer has announced that its experimental drug, designed to combat cancer cachexia—a serious condition causing weight and appetite loss in cancer patients—has shown promising results in a mid-stage trial. Patients who received the treatment experienced beneficial outcomes in terms of body weight, muscle mass, quality of life, and physical function. This drug, known as ponsegromab, is a monoclonal antibody and may become the first FDA-approved treatment specifically targeting cancer cachexia.
*Photo Credit: Kena Betancur, Corbis News via Getty Images*
In related health news, other top stories include:
1.
A 41-year-old, who recently completed the first civilian spacewalk, left high school early to build his $7 billion business.
2.
Dating experts advise avoiding bars for meeting potential romantic partners—suggesting better alternatives.
3.
Pfizer’s promising results from its cancer cachexia drug trial.
4.
DirecTV and Disney have resolved their dispute just in time for college football season, ending a blackout.
5.
A look at the nine college majors leading to the most fulfilling careers, with two of them averaging over $100,000 annually.
For more details, visit our full site.